Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Prashanth Rawla,1 Tagore Sunkara,2 Jeffrey Pradeep Raj3 1Department of Internal Medicine, Memorial Hospital of Martinsville and Henry County, Martinsville, VA, 2Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Clinical Affiliate of The Mount Sinai Hospital, New York, NY, US...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rawla P, Sunkara T, Raj JP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Inflammatory Bowel Disease Crohn's Disease Ulcerative Colitis Biologics Biosimilars Tumor Necrosis Factor Integrin Interleukin Adalimumab Humira Certolizumab Cimzia Golimumab Simponi Infliximab Remicade Vedolizumab Entyvio Natalizumab Tysabri Ustekinumab Stelara. Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/9fc73e3d92d743d19ad5b6e9c02efeb7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9fc73e3d92d743d19ad5b6e9c02efeb7
record_format	dspace
spelling	oai:doaj.org-article:9fc73e3d92d743d19ad5b6e9c02efeb72021-12-02T00:23:13ZRole of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives1178-7031https://doaj.org/article/9fc73e3d92d743d19ad5b6e9c02efeb72018-05-01T00:00:00Zhttps://www.dovepress.com/role-of-biologics-and-biosimilars-in-inflammatory-bowel-disease-curren-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Prashanth Rawla,1 Tagore Sunkara,2 Jeffrey Pradeep Raj3 1Department of Internal Medicine, Memorial Hospital of Martinsville and Henry County, Martinsville, VA, 2Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Clinical Affiliate of The Mount Sinai Hospital, New York, NY, USA; 3Department of Pharmacology, St John’s Medical College, Bangalore, India Abstract: Inflammatory bowel disease (IBD) is an idiopathic chronic inflammatory disease of the gastrointestinal system. The spectrum is of predominantly two types, namely, ulcerative colitis and Crohn’s disease. The incidence of IBD has been increasing steadily since 1990, and so the number of agents used in their treatment. Biologics that are derived partly or completely from living biological sources such as animals and humans have become widely available, which provide therapeutic benefits to the IBD patients. Currently, monoclonal antibodies against tumor necrosis factor-alpha (infliximab, adalimumab, certolizumab, and golimumab), integrins (vedolizumab and natalizumab), and interleukin (IL)-12 and IL-23 antagonists (ustekinumab) are approved for use in IBD. Biosimilars of infliximab and adalimumab are also available for the treatment of IBD. This review summarizes the clinical pharmacology, studies leading to their approval, overall indications and their use in IBD, usage in pregnancy and lactation, and the adverse effects of these agents. This review also summarizes the recent advances and future perspectives specific to biologics and biosimilars in IBD. Keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, biologics, biosimilars, tumor necrosis factor, integrin, interleukin, adalimumab, Humira®, certolizumab, Cimzia®, golimumab, Simponi®, infliximab, Remicade®, vedolizumab, Entyvio, natalizumab, Tysabri®, ustekinumab, Stelara® Rawla PSunkara TRaj JPDove Medical PressarticleInflammatory Bowel DiseaseCrohn's DiseaseUlcerative ColitisBiologicsBiosimilarsTumor Necrosis FactorIntegrinInterleukinAdalimumabHumiraCertolizumabCimziaGolimumabSimponiInfliximabRemicadeVedolizumabEntyvioNatalizumabTysabriUstekinumabStelara.PathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 11, Pp 215-226 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Inflammatory Bowel Disease Crohn's Disease Ulcerative Colitis Biologics Biosimilars Tumor Necrosis Factor Integrin Interleukin Adalimumab Humira Certolizumab Cimzia Golimumab Simponi Infliximab Remicade Vedolizumab Entyvio Natalizumab Tysabri Ustekinumab Stelara. Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	Inflammatory Bowel Disease Crohn's Disease Ulcerative Colitis Biologics Biosimilars Tumor Necrosis Factor Integrin Interleukin Adalimumab Humira Certolizumab Cimzia Golimumab Simponi Infliximab Remicade Vedolizumab Entyvio Natalizumab Tysabri Ustekinumab Stelara. Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Rawla P Sunkara T Raj JP Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
description	Prashanth Rawla,1 Tagore Sunkara,2 Jeffrey Pradeep Raj3 1Department of Internal Medicine, Memorial Hospital of Martinsville and Henry County, Martinsville, VA, 2Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Clinical Affiliate of The Mount Sinai Hospital, New York, NY, USA; 3Department of Pharmacology, St John’s Medical College, Bangalore, India Abstract: Inflammatory bowel disease (IBD) is an idiopathic chronic inflammatory disease of the gastrointestinal system. The spectrum is of predominantly two types, namely, ulcerative colitis and Crohn’s disease. The incidence of IBD has been increasing steadily since 1990, and so the number of agents used in their treatment. Biologics that are derived partly or completely from living biological sources such as animals and humans have become widely available, which provide therapeutic benefits to the IBD patients. Currently, monoclonal antibodies against tumor necrosis factor-alpha (infliximab, adalimumab, certolizumab, and golimumab), integrins (vedolizumab and natalizumab), and interleukin (IL)-12 and IL-23 antagonists (ustekinumab) are approved for use in IBD. Biosimilars of infliximab and adalimumab are also available for the treatment of IBD. This review summarizes the clinical pharmacology, studies leading to their approval, overall indications and their use in IBD, usage in pregnancy and lactation, and the adverse effects of these agents. This review also summarizes the recent advances and future perspectives specific to biologics and biosimilars in IBD. Keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, biologics, biosimilars, tumor necrosis factor, integrin, interleukin, adalimumab, Humira®, certolizumab, Cimzia®, golimumab, Simponi®, infliximab, Remicade®, vedolizumab, Entyvio, natalizumab, Tysabri®, ustekinumab, Stelara®
format	article
author	Rawla P Sunkara T Raj JP
author_facet	Rawla P Sunkara T Raj JP
author_sort	Rawla P
title	Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
title_short	Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
title_full	Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
title_fullStr	Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
title_full_unstemmed	Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
title_sort	role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/9fc73e3d92d743d19ad5b6e9c02efeb7
work_keys_str_mv	AT rawlap roleofbiologicsandbiosimilarsininflammatoryboweldiseasecurrenttrendsandfutureperspectives AT sunkarat roleofbiologicsandbiosimilarsininflammatoryboweldiseasecurrenttrendsandfutureperspectives AT rajjp roleofbiologicsandbiosimilarsininflammatoryboweldiseasecurrenttrendsandfutureperspectives
_version_	1718403756343689216

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Ejemplares similares